RICERCA ITALIANA     

Bibliografia

1)Turner HE, Harris AL, Melmed S, Wass JAH: Angiogenesis in endocrine tumors. Endocrine Review 24(5): 600-632, 2003
2)Folkman J: What is the evidence that tumours are angiogenesis dependent?. J Natl Cancer Inst 82: 4-6, 1990
3)Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, Post S: High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for adenocarcinoma of the pancreas. Pancreas 25(2): 122-129, 2002
4)Karademir S, Sokmen S, Terzi C, Sagol O, Ozer E, Astarcioglu H, Coker A, Astarcioglu I: Tumor angiogenesis as a prognostic predictor in pancreatic cancer. J Hepatobiliary Pancreat Surg 7: 489-495, 2000
5)Khorana AA, Hu YC, Ryan CK, Komorowski RA, Hostetter G, Ahrendt SA: Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer. Journal of Gastrointestinal Surgery 9 (7): 903-911, 2005
6)Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995
7) Hotz HG, Hines OJ, Hotz B, Foitzik T, Buhr HJ, Reber HA: Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. Journal of Gastrointestinal Surgery 7 (2): 220-228, 2003
8)Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991
9)La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C: Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Human Pathology 34: 18-27, 2003
10)Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88(10): 2239-2245, 2000
11)Raspollini MR, Amunni G, Villanucci A, Boddi V, Rossi Degl’Innocenti D, Taddei GL: Microvessel density in ovarian carcinoma: computer image analysis in patients with shorter and longer survival. Int J Gynecol Cancer 15: 844-849, 2005
12)Yao Y, Kubota T, Takeuchi H, Sato K: Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: Comparison with an anti-CD31 monoclonal antibody. Neuropathology 25: 201-206, 2005
13) Solcia E, Kloppel G & Sobin LH (eds). Histological typing of endocrine tumours. 2000, Springer verlag, New York.
14) Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds). Tumours of the lung, pleura, thymus and heart. WHO classification of tumours. 2004, Lyon.
15)Aguayo SM, Miller YE, Waldron JA Jr, Bogin RM, Sunday ME, Staton GW Jr, Beam WR, King TE Jr. Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med. 1992 Oct 29;327(18):1285-8.
16) Korkolopoulou P, Apostolidou E, Pavlopoulos PM, Kavantzas N, Vyniou N, Thymara I, Terpos E, Patsouris E, Yataganas X, Davaris P. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia. 2001 Sep;15(9):1369-76.
17) Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999 Feb 15;59(4):856-61.
18) Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol. 2004 Feb;35(2):176-83.
19) Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B, Tonini G. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004 Jun;57(6):591-7.
20)Hansen S, Sorensen FB, Vach W, Grabau DA, Bak M, Rose C. Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients. Histopathology. 2004 May;44(5):428-36.
21) Weidner N. The importance of tumor angiogenesis: the evidence continues to grow. Am J Clin Pathol. 2004 Nov;122(5):675-7.
22) Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat. 1995;36(2):193-204.
23) Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res. 1994 Oct;85(10):1045-9.
24) Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T, Tominaga T. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer. 1996 Mar 15;77(6):1101-6.
25) Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 Nov 18;285(21):1182-6.
26) Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res. 2000;79:1-38.
27) Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44.